The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Xu, Feng ^a   Zhao, Li Hua ^a   Su, Jian Bin ^a   Chen, Tong ^a   Wang, Xue Qin ^a   Chen, Jin Feng ^a   Wu, Gang ^a   Jin, Yan ^a   Wang, Xiao Hua ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Continuous glucose monitoring; Diabetic peripheral neuropathy; Glycemic variability; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84989204369     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-139     Document Type: Article

References (39)

1. Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ: Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 2002, 25:2010-2015.
2. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486.
3. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association: Diabetic neuropathies: A statement by the american diabetes association. Diabetes Care 2005, 28:956-962.
4. Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, Vinik A, Boulton A, on behalf of the Toronto Expert Panel on Diabetic Neuropathy: Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011, 27:629-638.
5. Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD: Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complicat 2007, 21:306-314.
6. Wang DD, Bakhotmah BA, Hu FB, Alzahrani HA: Prevalence and correlates of diabetic peripheral neuropathy in a saudi arabic population: A crosssectional study. PLoS One 2014, 9:e106935.
7. Won JC, Kwon HS, Kim CH, Lee JH, Park TS, Ko KS, Cha BY: Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea. Diabet Med 2012, 29:e290-e296.
8. Monnier L, Colette C, Owens DR: Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: A move towards a unified glucose tetrad concept. Diabetes Metab Res Rev 2009, 25:393-402.
9. Brownlee M, Hirsch IB: Glycemic variability: A hemoglobin A1cindependent risk factor for diabetic complications. JAMA 2006, 295:1707-1708.
10. Nalysnyk L, Hernandez-Medina M, Krishnarajah G: Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010, 12:288-298.
11. American Diabetes Association: Standards of medical care in diabetes-2011. Diabetes Care 2011, 34:S11-S61.
12. Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H, Endocrine Society: Continuous glucose monitoring: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:2968-2979.
13. Mauras N, Fox L, Englert K, Beck RW: Continuous glucose monitoring in type 1 diabetes. Endocrine 2013, 43:41-50.
14. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34:S62-S69.
15. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Toronto Diabetic Neuropathy Expert Group: Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33:2285-2293.
16. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR: Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther 2011, 13:921-928.
17. Zhou J, Jia W, Bao Y, Ma X, Lu W, Li H, Hu C, Xiang K: Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med Sci Monit 2008, 14:CR552-CR558.
18. Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, Jia W: Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit 2011, 17:CR9-CR13.
19. Monnier L, Mas E, Ginet C, Michel F, Villo LN, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
20. Kubiak T, Hermanns N, Schreckling HJ, Kulzer B, Haak T: Assessment of hypoglycaemia awareness using continuous glucose monitoring. Diabet Med 2004, 21:487-490.
21. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470.
22. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
23. Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E: Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 77:420-426.
24. Hay LC, Wilmshurst EG, Fulcher G: Unrecognized hypo-And hyperglycemia in well-controlled patients with type 2 diabetes mellitus: The results of continuous glucose monitoring. Diabetes Technol Ther 2003, 5:19-26.
25. Su JB, Wang XQ, Chen JF, Wu G, Jin Y: Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose. Chin Med J (Engl) 2011, 124:144-147.
26. Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y: The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-Term follow-up. Diabetes Res Clin Pract 2010, 89:296-302.
27. Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y: The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-Term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract 2011, 91:e40-e42.
28. Kilpatrick ES, Rigby AS, Atkin SL: A1C variability and the risk of microvascular complications in type 1 diabetes: data from the diabetes control and complications trial. Diabetes Care 2008, 31:2198-2202.
29. Lin CC, Chen CC, Chen FN, Li CI, Liu CS, Lin WY, Yang SY, Lee CC, Li TC: Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med 2013, 126:1017e1-1017e10.
30. Sartore G, Chilelli NC, Burlina S, Lapolla A: Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol 2013, 50:437-442.
31. Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ: The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: A pilot study. Diabet Med 2002, 19:870-873.
32. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
33. Brownlee M: The pathophysiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54:1615-1625.
34. Torimoto K, Okada Y, Mori H, Tanaka Y: Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol 2013, 12:1.
35. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C: Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011, 10:19.
36. Su G, Mi SH, Li Z, Tao H, Yang HX, Zheng H: Prognostic value of early in-hospital glycemic excursion in elderly patients with acute myocardial infarction. Cardiovasc Diabetol 2013, 12:33.
37. Su G, Mi SH, Tao H, Li Z, Yang HX, Zheng H, Zhou Y, Tian L: Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care 2013, 36:1026-1032.
38. Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR: The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr 2012, 4:21.
39. Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TL, BARI 2D Study Group: Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) cohort. Diabetes Care 2013, 36:3208-3215.